Clinical Trial Update: Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update reporting results for the combination of cabergoline and pasireotide in non-functioning pituitary adenomas and resistant prolact…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-functioning Pituitary Adenomas
• Prolactinomas

Drugs mentioned

• CABERGOLINE (CABERGOLINE)
• Pasireotide (pasireotide)

Snippet

Sponsor: Universidade Federal do Rio de Janeiro | Conditions: Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-06-16